Excelsior Sciences key facts
as of Oct 2026- Operator of an automated chemistry platform intended to accelerate the discovery and manufacture of small molecules.
- Excelsior Sciences is valued at approximately $96.0M as of Oct 2026 (last reported valuation).
- It has raised $70.0M; the latest was Grant ($25.0M) in Dec 2025.
- Notable investors include Khosla Ventures, Massachusetts Institute of Technology, Sofinnova Partners, Deerfield Management, Illinois Ventures — 8 tracked in total.
- Status: Privately Held (backing).
Excelsior Sciences's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·Watch Excelsior Sciences: the Monday email on marks, rounds and moves
Excelsior Sciences funding rounds
No funding rounds for Excelsior Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Excelsior Sciences valuation
Excelsior Sciences's last reported valuation was $96 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Excelsior Sciences investors
8 investors are on record for Excelsior Sciences, including Khosla Ventures, Massachusetts Institute of Technology, Sofinnova Partners and Deerfield Management.
About Excelsior Sciences
Operator of an automated chemistry platform intended to accelerate the discovery and manufacture of small molecules. The company offers modular, synthesis-ready and AI-readable chemical building blocks used as tokens in a machine-executable chemical language, enabling researchers and industries working with small molecules to speed up development, generate new functional possibilities, and achieve more efficient and sustainable outcomes.
- Sector
- Business Products and Services (B2B)
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 18
- Website
- excelsiorsci.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.